Active, not recruitingInterventional · Phase 3NCT01901094 ↗A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Active, not recruitingInterventional · Phase 2/3NCT02339571 ↗Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV MelanomaBarbara MaPIInterventionProcedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Biological: Ipilimumab · Procedure: Magnetic Resonance Elastography · Procedure: Multigated Acquisition Scan · Biological: Nivolumab · Biological: SargramostimDatesNov 2015 – Jun 2033 (est.)SponsorECOG-ACRIN Cancer Research GroupStage III Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
Active, not recruitingInterventional · Not applicableNCT02659215 ↗A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast® With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to ControlGraeme WhytePIInterventionDevice: Hyalofast · Procedure: MicrofractureDatesDec 2015 – Mar 2025SponsorAnika Therapeutics, Inc.Defect of Articular Cartilage
Active, not recruitingInterventional · Phase 3NCT02954874 ↗A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant ChemotherapyEleni AndreopoulouPIInterventionProcedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis · Other: Patient Observation · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation TherapyDatesJan 2017 – Aug 2026SponsorSouthwest Oncology GroupBreast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more
Active, not recruitingInterventional · Phase 2NCT03375307 ↗A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair DefectsCora SternbergPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Bone Scan · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Olaparib · Procedure: Positron Emission TomographyDatesNov 2020 – Dec 2026 (est.)SponsorNational Cancer InstituteAdvanced Bladder CarcinomaAdvanced Genitourinary System CarcinomaMetastatic Bladder Carcinoma+3 more
Active, not recruitingInterventional · Phase 3NCT03533582 ↗Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)Alexander Ja-Ho ChouPIInterventionProcedure: Biospecimen Collection · Drug: Carboplatin · Drug: Cisplatin · Drug: Doxorubicin · Drug: Etoposide · Drug: Fluorouracil · Drug: Gemcitabine · Drug: Irinotecan · Drug: Oxaliplatin · Other: Patient Observation · Procedure: Resection · Drug: Sorafenib · Drug: Vincristine SulfateDatesMay 2018 – Mar 2027 (est.)SponsorChildren's Oncology GroupChildhood Hepatocellular CarcinomaChildhood Malignant Liver NeoplasmFibrolamellar Carcinoma+2 more
Active, not recruitingInterventional · Phase 2NCT03600701 ↗A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung CancerAshish SaxenaPIInterventionDrug: Atezolizumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Cobimetinib · Procedure: Computed Tomography · Procedure: Magnetic Resonance ImagingDatesNov 2018 – Jul 2025· Results postedSponsorNational Cancer InstituteMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+1 more
Active, not recruitingInterventional · Phase 2/3NCT03604991 ↗A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction AdenocarcinomaManish A ShahPIInterventionProcedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Ipilimumab · Biological: Nivolumab · Drug: Paclitaxel · Procedure: Positron Emission Tomography · Radiation: Radiation TherapyDatesMay 2019 – Mar 2027 (est.)SponsorECOG-ACRIN Cancer Research GroupClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+5 more
RecruitingInterventional · Phase 2NCT03606967 ↗Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerMassimo CristofanilliPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Durvalumab · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Nab-paclitaxel · Biological: Personalized Synthetic Long Peptide Vaccine · Drug: Poly ICLC · Biological: Sacituzumab Govitecan · Biological: TremelimumabDatesApr 2021 – Dec 2026 (est.)SponsorNational Cancer InstituteAnatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma
RecruitingInterventional · Phase 3NCT03678025 ↗Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate CancerDouglas S ScherrPIInterventionDrug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: TriptorelinDatesSep 2018 – Apr 2033 (est.)SponsorSouthwest Oncology GroupCastration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more
Active, not recruitingInterventional · Phase 2/3NCT03701308 ↗A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyGail J RobozPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Drug: Daunorubicin · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: UproleselanDatesMar 2019 – Oct 2024· Results postedSponsorAlliance for Clinical Trials in OncologyAcute Myeloid Leukemia
Active, not recruitingInterventional · Phase 3NCT03725059 ↗A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)Eleni AndreopoulouPIInterventionBiological: Pembrolizumab (K) · Drug: Placebo (P) · Drug: Paclitaxel (X) · Drug: Doxorubicin (A) · Drug: Epirubicin (E) · Drug: Cyclophosphamide (C) · Drug: Endocrine therapy · Radiation: Radiation therapy · Procedure: SurgeryDatesDec 2018 – Jan 2031 (est.)SponsorMerck & Co., Inc.Breast Cancer
RecruitingInterventional · Phase 2NCT03739814 ↗A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory DiseaseEllen K. RitchiePIInterventionProcedure: Biospecimen Collection · Biological: Blinatumomab · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Biological: Inotuzumab Ozogamicin · Procedure: Lumbar Puncture · Drug: PonatinibDatesMay 2019 – Feb 2027 (est.)SponsorAlliance for Clinical Trials in OncologyB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
Active, not recruitingInterventional · Phase 3NCT03793166 ↗PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]Ana M. MolinaPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib · Procedure: Computed Tomography · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Other: Quality-of-Life Assessment · Other: Questionnaire AdministrationDatesJun 2019 – Mar 2028 (est.)SponsorAlliance for Clinical Trials in OncologyClear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+6 more
Active, not recruitingInterventional · Phase 3NCT03811015 ↗A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCCHani Lamie AshamallaPIInterventionProcedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Echocardiography Test · Other: Fludeoxyglucose F-18 · Radiation: Intensity-Modulated Radiation Therapy · Biological: Nivolumab · Other: Patient Observation · Procedure: Positron Emission TomographyDatesAug 2019 – Jan 2030 (est.)SponsorECOG-ACRIN Cancer Research GroupClinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
RecruitingInterventional · Phase 1NCT03816345 ↗A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)Ashish SaxenaPIInterventionProcedure: Biospecimen Collection · Drug: Cabozantinib · Drug: Fluoropyrimidine · Biological: Ipilimumab · Biological: Nivolumab · Drug: Platinum Compound · Drug: Platinum DoubletDatesJul 2019 – Mar 2028 (est.)SponsorNational Cancer InstituteAutoimmune DiseaseCrohn DiseaseDermatomyositis+11 more
Active, not recruitingInterventional · Phase 2NCT03817398 ↗Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)Alexander Ja-Ho ChouPIInterventionProcedure: Biospecimen Collection · Other: Drug Withdrawn · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Tyrosine Kinase InhibitorDatesNov 2019 – Sep 2026 (est.)SponsorChildren's Oncology GroupChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
RecruitingInterventional · Phase 2NCT03866382 ↗A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)Cora SternbergPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib S-malate · Procedure: Computed Tomography · Procedure: Echocardiography Test · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission TomographyDatesMay 2019 – Feb 2027 (est.)SponsorAlliance for Clinical Trials in OncologyBladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more
Active, not recruitingInterventional · Phase 3NCT03900429 ↗A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic DecompensationSonal KumarPIInterventionDrug: MGL-3196 · Drug: Placebo · Procedure: Liver BiopsyDatesMar 2019 – Jan 2028 (est.)SponsorMadrigal Pharmaceuticals, Inc.NASH - Nonalcoholic Steatohepatitis
Active, not recruitingInterventional · Phase 3NCT03907488 ↗A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin LymphomaJia RuanPIInterventionProcedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Biological: Filgrastim · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Biological: Pegfilgrastim · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Vinblastine SulfateDatesAug 2019 – Mar 2024· Results postedSponsorSouthwest Oncology GroupAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma+7 more